Methylated Circulating Tumor DNA in Blood: Power in Cancer Prognosis and Response

Overview

Journal Endocr Relat Cancer

Specialties Endocrinology
Oncology

Date 2016 Jan 15

PMID 26764421

Citations 79

Authors

Kristina Warton

Kate L Mahon

Goli Samimi

Affiliations

Soon will be listed here.

Abstract

Circulating tumor DNA (ctDNA) in the plasma or serum of cancer patients provides an opportunity for non-invasive sampling of tumor DNA. This 'liquid biopsy' allows for interrogations of DNA such as quantity, chromosomal alterations, sequence mutations and epigenetic changes, and can be used to guide and improve treatment throughout the course of the disease. This tremendous potential for real-time 'tracking' in a cancer patient has led to substantial research efforts in the ctDNA field. ctDNA can be distinguished from non-tumor DNA by the presence of tumor-specific mutations and copy number variations, and also by aberrant DNA methylation, with both DNA sequence and methylation changes corresponding to those found in the tumor. Aberrant methylation of specific promoter regions can be a very consistent feature of cancer, in contrast to mutations, which typically occur at a wide range of sites. This consistency makes ctDNA methylation amenable to the design of widely applicable clinical assays. In this review, we examine ctDNA methylation in the context of monitoring disease status, treatment response and determining the prognosis of cancer patients.

Citing Articles

Circulating tumor DNA methylation detection as biomarker and its application in tumor liquid biopsy: advances and challenges.

Li L, Sun Y MedComm (2020). 2024; 5(11):e766.

PMID: 39525954 PMC: 11550092. DOI: 10.1002/mco2.766.

T cell exhaustion methylation signature drives differential immune responses in glioblastoma.

Chen F, Qian W, Chen Z, Qian J, Luo C Discov Oncol. 2024; 15(1):530.

PMID: 39377985 PMC: 11461406. DOI: 10.1007/s12672-024-01412-3.

Epigenetic reprogramming in gastrointestinal cancer: biology and translational perspectives.

Wang Y, Zhang M, Xu J, Zheng L, Liu P, Chen J MedComm (2020). 2024; 5(9):e670.

PMID: 39184862 PMC: 11344282. DOI: 10.1002/mco2.670.

Focused Ultrasound-Enhanced Liquid Biopsy: A Promising Diagnostic Tool for Brain Tumor Patients.

Bakker A, Ixkes A, Venugopal H, Ries M, Lak N, de Vos F Cancers (Basel). 2024; 16(8).

PMID: 38672658 PMC: 11049441. DOI: 10.3390/cancers16081576.

Dissection of transcriptomic and epigenetic heterogeneity of grade 4 gliomas: implications for prognosis.

Zeng C, Song X, Zhang Z, Cai Q, Cai J, Horbinski C Acta Neuropathol Commun. 2023; 11(1):133.

PMID: 37580817 PMC: 10426201. DOI: 10.1186/s40478-023-01619-5.

References

Sharma G, Mirza S, Parshad R, Gupta S, Ralhan R . DNA methylation of circulating DNA: a marker for monitoring efficacy of neoadjuvant chemotherapy in breast cancer patients. Tumour Biol. 2012; 33(6):1837-43. DOI: 10.1007/s13277-012-0443-y. View

Heyn H, Esteller M . DNA methylation profiling in the clinic: applications and challenges. Nat Rev Genet. 2012; 13(10):679-92. DOI: 10.1038/nrg3270. View

Kim Y, Jin D, Lee B, Cho E, Han J, Shim Y . RARβ2 hypermethylation is associated with poor recurrence-free survival in never-smokers with adenocarcinoma of the lung. Clin Epigenetics. 2015; 7:32. PMC: 4371724. DOI: 10.1186/s13148-015-0066-4. View

Li F, Yang Y, Wang X, Hong Y, Wang N, Chen Z . Promoter methylation of DAPK gene may contribute to the pathogenesis of nonsmall cell lung cancer: a meta-analysis. Tumour Biol. 2014; 35(6):6011-20. DOI: 10.1007/s13277-014-1796-1. View

Sharma G, Mirza S, Parshad R, Srivastava A, Gupta S, Pandya P . Clinical significance of promoter hypermethylation of DNA repair genes in tumor and serum DNA in invasive ductal breast carcinoma patients. Life Sci. 2010; 87(3-4):83-91. DOI: 10.1016/j.lfs.2010.05.001. View

Fischer J, Ohnmacht U, Rieger N, Zemaitis M, Stoffregen C, Kostrzewa M . Promoter methylation of RASSF1A, RARbeta and DAPK predict poor prognosis of patients with malignant mesothelioma. Lung Cancer. 2006; 54(1):109-16. DOI: 10.1016/j.lungcan.2006.06.017. View

Wong T, Kwong D, Sham J, Wei W, Kwong Y, Yuen A . Quantitative plasma hypermethylated DNA markers of undifferentiated nasopharyngeal carcinoma. Clin Cancer Res. 2004; 10(7):2401-6. DOI: 10.1158/1078-0432.ccr-03-0139. View

Mahon K, Qu W, Devaney J, Paul C, Castillo L, Wykes R . Methylated Glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer. Br J Cancer. 2014; 111(9):1802-9. PMC: 4453725. DOI: 10.1038/bjc.2014.463. View

Castro M, Grau L, Puerta P, Gimenez L, Venditti J, Quadrelli S . Multiplexed methylation profiles of tumor suppressor genes and clinical outcome in lung cancer. J Transl Med. 2010; 8:86. PMC: 2955578. DOI: 10.1186/1479-5876-8-86. View

10.

Garcia-Baquero R, Puerta P, Beltran M, Alvarez-Mujica M, Alvarez-Ossorio J, Sanchez-Carbayo M . Methylation of tumor suppressor genes in a novel panel predicts clinical outcome in paraffin-embedded bladder tumors. Tumour Biol. 2014; 35(6):5777-86. DOI: 10.1007/s13277-014-1767-6. View

11.

Pappas J, Toulouse A, Basik M, Levesque L, Bradley W . Knockdown of RARB2 identifies a dual role in cancer. Genes Chromosomes Cancer. 2011; 50(9):700-14. DOI: 10.1002/gcc.20892. View

12.

Ellinger J, El Kassem N, Heukamp L, Matthews S, Cubukluoz F, Kahl P . Hypermethylation of cell-free serum DNA indicates worse outcome in patients with bladder cancer. J Urol. 2007; 179(1):346-52. DOI: 10.1016/j.juro.2007.08.091. View

13.

Hoshimoto S, Kuo C, Chong K, Takeshima T, Takei Y, Li M . AIM1 and LINE-1 epigenetic aberrations in tumor and serum relate to melanoma progression and disease outcome. J Invest Dermatol. 2012; 132(6):1689-97. PMC: 3352986. DOI: 10.1038/jid.2012.36. View

14.

Ling Z, Zhao Q, Zhou S, Mao W . MSH2 promoter hypermethylation in circulating tumor DNA is a valuable predictor of disease-free survival for patients with esophageal squamous cell carcinoma. Eur J Surg Oncol. 2012; 38(4):326-32. DOI: 10.1016/j.ejso.2012.01.008. View

15.

Diehl F, Schmidt K, Choti M, Romans K, Goodman S, Li M . Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008; 14(9):985-90. PMC: 2820391. DOI: 10.1038/nm.1789. View

16.

Yagyu S, Gotoh T, Iehara T, Miyachi M, Katsumi Y, Tsubai-Shimizu S . Circulating methylated-DCR2 gene in serum as an indicator of prognosis and therapeutic efficacy in patients with MYCN nonamplified neuroblastoma. Clin Cancer Res. 2008; 14(21):7011-9. DOI: 10.1158/1078-0432.CCR-08-1249. View

17.

Umbricht C, Evron E, Gabrielson E, Ferguson A, Marks J, Sukumar S . Hypermethylation of 14-3-3 sigma (stratifin) is an early event in breast cancer. Oncogene. 2001; 20(26):3348-53. DOI: 10.1038/sj.onc.1204438. View

18.

Meiers I, Shanks J, Bostwick D . Glutathione S-transferase pi (GSTP1) hypermethylation in prostate cancer: review 2007. Pathology. 2007; 39(3):299-304. DOI: 10.1080/00313020701329906. View

19.

Bollati V, Baccarelli A, Hou L, Bonzini M, Fustinoni S, Cavallo D . Changes in DNA methylation patterns in subjects exposed to low-dose benzene. Cancer Res. 2007; 67(3):876-80. DOI: 10.1158/0008-5472.CAN-06-2995. View

20.

Zhang B, Chen D, Xia W, Zhang J, Wang F, Xu J . Real-time monitoring efficiency and toxicity of chemotherapy in patients with advanced lung cancer. Clin Epigenetics. 2015; 7:119. PMC: 4635986. DOI: 10.1186/s13148-015-0150-9. View